Mario Gabelli is Selling These 5 Stocks in 2022

2. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 43

Moderna, Inc. (NASDAQ:MRNA) operates as a biotechnology company that develops and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. As of May 19, shares of Moderna, Inc. (NASDAQ:MRNA) have dipped 13.61% over the past twelve months, and it is among the top 15 stocks that Mario Gabelli has sold in Q1 2022.

On May 17, Piper Sandler analyst Edward Tenthoff lowered his price target on Moderna, Inc. (NASDAQ:MRNA) to $214 from $348 backing his lowered revenue expectations for Spikevax, Moderna, Inc.’s (NASDAQ:MRNA) latest COVID-19 vaccination. The analyst maintained an Overweight rating on the shares but decreased his peak revenue estimates from Spikevax to value at $20.65 billion, down from his prior estimate of $94.7 billion.

At the end of Q4 2021, 43 hedge funds were bullish on Moderna, Inc. (NASDAQ:MRNA) with stakes worth $3.88 billion. This is compared to 49 positions in the previous quarter with stakes of $7.31 billion.

Carillon Tower Advisers mentioned Moderna, Inc. (NASDAQ:MRNA) in their third-quarter 2021 investor letter, here is what they said:

“Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The stock proved to be an impressive contributor once again in the quarter, as investors continue to evaluate the potential for future growth driven primarily by the firm’s revolutionary COVID-19 vaccine. Strong global demand for the vaccine may persist for the foreseeable future in order to maintain immunity as well as provide protection against any additional future variants. The potential for the firm’s mRNA technology to be used in a number of other use cases, specifically influenza, could also provide an additional tailwind for future growth.”